Last updated: February 19, 2026

ORTHO CYCLEN-28, a combined oral contraceptive containing norgestimate and ethinyl estradiol, faces a mature market characterized by significant generic competition and evolving regulatory landscapes. Its financial trajectory is influenced by declining market share, patent expiries of key components, and the ongoing shift towards newer contraceptive technologies.

What is ORTHO CYCLEN-28's Current Market Position?

ORTHO CYCLEN-28 is a prescription-only oral contraceptive pill. It is indicated for the prevention of pregnancy. The drug is formulated as a 28-day regimen, comprising 21 active pills and 7 placebo pills.

Active Ingredients: Norgestimate (a progestin) and Ethinyl Estradiol (an estrogen).
Mechanism of Action: It prevents ovulation, alters cervical mucus to inhibit sperm penetration, and modifies the uterine lining to reduce the likelihood of implantation.
Formulation: Typically available as a single-strength tablet.

The market for combined oral contraceptives is a well-established segment of the pharmaceutical industry. However, ORTHO CYCLEN-28, while historically significant, now competes in a crowded space.

Market Share: While specific current market share data for ORTHO CYCLEN-28 alone is not publicly granular, the overall market for generic norgestimate/ethinyl estradiol combination pills is substantial but fragmented. Branded ORTHO CYCLEN-28's share has eroded significantly due to generic entry.
Competition: Key competitors include a multitude of generic manufacturers offering equivalent formulations, as well as branded and generic contraceptives with different progestins, dosages, or delivery methods (e.g., vaginal rings, transdermal patches, intrauterine devices).

What are the Key Patent Expiries Affecting ORTHO CYCLEN-28?

The patent landscape for ORTHO CYCLEN-28 is complex, with primary patents on the active ingredients and their combinations having expired.

Norgestimate Patents: The foundational patents for norgestimate have long expired. For example, U.S. Patent 4,424,342, covering norgestimate, expired in the early 2000s. [1]
Ethinyl Estradiol Patents: Similarly, patents related to ethinyl estradiol, a widely used synthetic estrogen in oral contraceptives, expired decades ago.
Formulation and Method of Use Patents: While the core composition patents have expired, secondary patents related to specific formulations, manufacturing processes, or methods of use may have existed. However, these are generally less impactful in preventing generic entry compared to compound patents, especially once generics demonstrate bioequivalence.
Generic Entry Dates: Generic versions of norgestimate and ethinyl estradiol combination pills began entering the market approximately from the mid-2000s onward, following the expiry of key patents. This led to rapid price erosion and a significant decrease in the market share of the branded product.

The lack of active patent protection on the core drug entity for ORTHO CYCLEN-28 means the product is entirely reliant on market dynamics rather than intellectual property exclusivity for its future revenue.

How Have Regulatory Changes Impacted ORTHO CYCLEN-28?

Regulatory actions and policy shifts have influenced the market for ORTHO CYCLEN-28, primarily through mechanisms that promote generic competition and drug pricing.

Generic Drug Approval Pathways: The U.S. Food and Drug Administration (FDA) maintains abbreviated new drug application (ANDA) pathways, which allow generic manufacturers to seek approval for drug products that are bioequivalent to a reference listed drug (RLD). ORTHO CYCLEN-28 has served as an RLD, facilitating the entry of multiple generic versions. [2]
Hatch-Waxman Act: The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) is foundational to the generic drug market. It balances incentives for innovation with timely access to lower-cost generics by providing market exclusivity for new drugs and facilitating generic drug approval after patent expiry. [3]
Affordable Care Act (ACA): The ACA expanded access to preventive services, including contraception, without cost-sharing for many individuals. While this broadly benefited the contraceptive market, it also intensified competition as insurers encouraged the use of lower-cost generic options. [4]
FDA Orange Book: The FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (commonly known as the Orange Book) lists drugs that have been approved for marketing. It identifies which products are therapeutically equivalent to approved RLDs and includes patent and exclusivity information, crucial for understanding generic entry timelines. ORTHO CYCLEN-28's listing in the Orange Book has been critical for generic manufacturers. [2]
Labeling and Safety Updates: Like all pharmaceuticals, ORTHO CYCLEN-28 is subject to ongoing safety monitoring and potential labeling updates by regulatory agencies. While not directly linked to patent expiry, such changes can influence prescribing patterns and market demand.

The regulatory environment has consistently favored the introduction and accessibility of generic alternatives, thereby directly impacting the pricing power and market share of branded drugs like ORTHO CYCLEN-28.

What is the Financial Performance and Outlook for ORTHO CYCLEN-28?

The financial performance of ORTHO CYCLEN-28 has been negatively impacted by generic competition and market shifts. Its outlook is characterized by continued revenue decline.

Revenue Trends: Detailed historical revenue figures specifically for branded ORTHO CYCLEN-28 are difficult to isolate as sales are often consolidated with other products by the manufacturer. However, industry-wide data for combined oral contraceptives with expired patents consistently show a sharp decline in branded product revenue post-generic entry.
Pricing Dynamics: The introduction of generics leads to significant price reductions. The average selling price (ASP) of ORTHO CYCLEN-28 has decreased substantially from its peak. Generic versions are typically priced at a fraction of the branded product's original price.
Market Size of Norgestimate/Ethinyl Estradiol Generics: The U.S. market for generic norgestimate/ethinyl estradiol 0.25mg/0.035mg tablets is estimated to be in the tens of millions of dollars annually, but this is distributed among numerous manufacturers. [5]
Prescription Volume: Prescription volumes for branded ORTHO CYCLEN-28 have likely declined, with a corresponding increase in prescriptions for generic equivalents. Data from IQVIA or similar market research firms would show this trend, indicating a shift from branded to generic prescriptions. [6]
Future Revenue Projections: The financial trajectory for ORTHO CYCLEN-28 is projected to be a continued, albeit slower, decline in revenue. Without any new patent protection or significant product differentiation, it will remain subject to intense price competition.
Manufacturer Strategy: Manufacturers of branded ORTHO CYCLEN-28 have likely shifted their R&D and marketing focus to newer, patent-protected contraceptive products or diversified into other therapeutic areas. The product likely operates in a "low-touch" sales and marketing model.

The financial outlook is bleak for the branded product itself, with its revenue stream continuing to diminish as generics dominate the market.

What are the Emerging Trends in the Contraceptive Market?

The contraceptive market is dynamic, with innovation and patient preference driving shifts away from older oral contraceptive formulations.

Long-Acting Reversible Contraceptives (LARCs): LARCs, such as intrauterine devices (IUDs) and subdermal implants, are gaining popularity due to their high efficacy, convenience, and long duration of action (up to 3-10 years depending on the device). Examples include Mirena, Kyleena, Nexplanon. [7]
Hormonal IUDs: These devices release a progestin (e.g., levonorgestrel) directly into the uterus, offering localized effects and reducing systemic hormone exposure.
Non-Hormonal Contraceptives: There is growing interest in non-hormonal options, such as fertility awareness-based methods and barrier methods, driven by concerns about hormonal side effects.
Alternative Delivery Systems: While oral contraceptives remain common, there is a steady market for patches, vaginal rings, and injections, offering alternatives for women who have difficulty with daily pill regimens.
Digital Health and Apps: Fertility tracking apps and digital platforms are also emerging as tools for family planning, though their contraceptive efficacy varies.
Focus on Personalized Medicine: Research is ongoing to develop contraceptives tailored to individual women's genetic profiles and health histories to minimize side effects and optimize efficacy.
Evolving Formulations: While ORTHO CYCLEN-28 uses established hormone combinations, newer oral contraceptives feature different progestins (e.g., drospirenone, dienogest) that may offer different side effect profiles or benefits.

These trends indicate a market evolving beyond basic oral contraceptives, with a focus on convenience, efficacy, safety, and personalized options. ORTHO CYCLEN-28, as a foundational oral contraceptive, is less aligned with these forward-looking market demands.

What are the Key Competitive Threats to ORTHO CYCLEN-28?

The primary competitive threats to ORTHO CYCLEN-28 stem from genericization and the emergence of superior contraceptive alternatives.

Generic Erosion: The most significant and ongoing threat is the availability of numerous generic versions of norgestimate/ethinyl estradiol. These generics are bioequivalent and offered at a substantially lower cost, making them the preferred choice for most payers and a majority of prescribers and patients.
Advancements in Contraceptive Technology: Newer contraceptive methods, particularly LARCs, offer higher efficacy rates and greater convenience compared to daily oral pills. Their increasing adoption directly siphons market share from traditional oral contraceptives.
Differentiated Branded Oral Contraceptives: Even within the oral contraceptive market, newer branded products with different hormone combinations (e.g., drospirenone-containing pills) may offer perceived benefits in terms of reduced side effects (like acne or weight gain) or improved cycle control, drawing market share from older formulations.
Shifting Patient and Physician Preferences: There is a growing awareness and preference among both patients and healthcare providers for contraceptive methods that offer greater convenience and potentially fewer systemic side effects. This trend favors LARCs and alternative delivery systems over daily oral pills.
Payer Formulary Exclusions and Restrictions: Pharmacy benefit managers (PBMs) and insurance companies often place generic oral contraceptives on preferred tiers of their formularies and may restrict coverage for older branded products or newer, more expensive alternatives if effective generic options are available.
Regulatory Incentives for Generics: As discussed, regulatory frameworks are designed to facilitate generic competition, ensuring a continuous threat to branded products once patents expire.

These factors collectively diminish the market relevance and financial viability of ORTHO CYCLEN-28.

Key Takeaways

ORTHO CYCLEN-28 operates in a mature market segment with extensive generic competition following the expiry of its core patent protections.
The financial trajectory of branded ORTHO CYCLEN-28 is characterized by significant revenue decline due to price erosion and market share loss to generics.
Regulatory frameworks, such as the Hatch-Waxman Act and FDA's ANDA approval process, have facilitated the widespread availability of generic norgestimate/ethinyl estradiol combinations.
Emerging trends in the contraceptive market, including the rise of LARCs and alternative delivery systems, present a competitive challenge by offering greater efficacy and convenience.
The primary competitive threat remains generic erosion, coupled with shifting patient and physician preferences towards newer contraceptive technologies.

Frequently Asked Questions

What is the current patent status of ORTHO CYCLEN-28? The foundational patents for the active ingredients (norgestimate and ethinyl estradiol) and their basic combinations have expired, permitting generic manufacturing.
How has generic competition affected the price of ORTHO CYCLEN-28? Generic entry has led to substantial price reductions, with the average selling price of branded ORTHO CYCLEN-28 significantly lower than its historical peak.
Are there newer versions of ORTHO CYCLEN-28 with extended patent protection? No, ORTHO CYCLEN-28 refers to the specific formulation of norgestimate and ethinyl estradiol. While other oral contraceptives using these or similar hormones exist, they are distinct products with their own patent and market profiles.
What are the main advantages of newer contraceptive methods over ORTHO CYCLEN-28? Newer methods, particularly LARCs, offer higher efficacy rates, longer duration of action, and greater convenience (e.g., not requiring daily adherence).
Will ORTHO CYCLEN-28 be discontinued due to low sales? Discontinuation depends on the manufacturer's strategic decisions regarding profitability and resource allocation. Given its mature status and generic competition, it is unlikely to be a growth product, but manufacturers may continue to produce it if there is a demonstrable market demand and profit margin, however small.

Citations

[1] U.S. Patent 4,424,342. (1983). Norgestimate, a stereoisomer of 13-ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one oxime. Google Patents. Retrieved from https://patents.google.com/patent/US4424342A/en

[2] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Department of Health and Human Services. Retrieved from https://www.fda.gov/drugs/drug-approvals/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

[3] U.S. Food and Drug Administration. (2020, May 15). The Hatch-Waxman Act and the Prescription Drug Market. Retrieved from https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/hatch-waxman-act-and-prescription-drug-market

[4] Kaiser Family Foundation. (2020, March 10). Contraception Coverage Under the ACA. Retrieved from https://www.kff.org/womens-health/issue-brief/contraception-coverage-under-the-aca/

[5] Grand View Research. (2023, February). Oral Contraceptives Market Size, Share & Trends Analysis Report By Type (Combined, Progestin-Only), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 – 2030. (Report available for purchase, general market size estimates derived from publicly available executive summaries and industry reports).

[6] IQVIA. (Various Publications). Pharmaceutical market data and analytics. (Subscription-based services, specific data points not publicly accessible for direct citation).

[7] World Health Organization. (2023, March 29). Long-acting reversible contraception (LARC). Retrieved from https://www.who.int/news-room/fact-sheets/detail/long-acting-reversible-contraception-larc

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	20
Patent Applications:	735
DailyMed Link:	ORTHO CYCLEN-28 at DailyMed

Sponsor	Phase
Gilead Sciences	Phase 1
Lexicon Pharmaceuticals	Phase 1
Aegerion Pharmaceuticals, Inc.	Phase 1

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	ORTHO CYCLEN-28	ethinyl estradiol; norgestimate	TABLET;ORAL-28	019653-002	Dec 29, 1989		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

ORTHO CYCLEN-28 Drug Patent Profile

When do Ortho Cyclen-28 patents expire, and when can generic versions of Ortho Cyclen-28 launch?

AI Deep Research

Questions you can ask:

Summary for ORTHO CYCLEN-28

Recent Clinical Trials for ORTHO CYCLEN-28

US Patents and Regulatory Information for ORTHO CYCLEN-28

ORTHO CYCLEN-28: Market Dynamics and Financial Trajectory